Study finds that a drug used to treat alcoholism XR-Naltrexone may be used to suppress HIV levels

Recently, researchers at Yale University in the United States published a study (INSPIRE) in the Journal of AIDS (INSPIRE) showing that aFDA(approved for the treatment of alcohol-relateddrug(XR-Naltrexone) can help antiviral treatment and inhibit HIV levels in HIV-infected people/AIDS patientsnonspecific opioid receptor antagonistsnaloxone, are commonly used to treat alcohol and opioid addictionLow-dose naltrexone has been used to treat people living with HIV/AIDS since the 1980s2001, in vitro studies by the Minneapolis Medical Research Foundation, Hennepin County Medical Center and the Institute of Brain and Immunology At the University of Minnesota School of Medicine found that while the alone use of nalquone does not affect HIV-1 expression in CD4-plus lymphocytes, nalquone increases the activity of the antiretroviral drugs AZT (Zidovdine) and indinavir (dinavir) by 2 to 3 timesStudies similar to those of the anti-opioid receptor (KOR) support the role of KOR's possible involvement in naltrexone to enhance the activity of antiretroviral drugsinspireINSPIRE is a double-blind, randomized, placebo-contrast editedin a connecticut prison(100 HIV-infected inmates who were about to be released between 2010 and 2016, while suffering from alcohol ism (AUD)The subjects were randomly divided into two groups on a 2:1 scale, receiving a monthly, six-month, reprieve or placebo injection, starting a week before the patient was released from prisonresearchers found that the ketone group either maintained or increased inhibition of HIV levelsThe proportion of naloxone viruses suppressed rose from 31% at baseline to 56.7% at six months, while the placebo group decreased from 42% to 30.3% The criterion for evaluating HIV suppression is that THE number of RNA copies is less than 50/ml The results of the trial analysis (it is believed that the treatment of reprieve naloxone can independently predict viral suppression.) the significance of the experiment is not limited to treating people living with HIV/AIDS with naloxone, but is to actively help newly released patients stick to their course of treatment